FY2021 · ended Dec 31, 2021 · Revenue $300,000 · Filed Mar 23, 2023
Bioatla, Inc. (BCAB) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $1.5 million in cash and investments and $5.9 million in total debt.
Revenue (TTM)
$300,000
Net income (TTM)
$-124.08M
-21.3% vs year-ago TTM
Operating cash flow (TTM)
$-23.48M
+55.1% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-2.66
Dividend per share
None
Shares outstanding
63.46M
+9.2% vs prior year
Net cash
$-4.32M
as of Jun 30, 2026
Operating margin
-43237.0%
FY 2023
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCAB (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1826892
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $300,000 |
| Operating income | -$59.3M | -$73.9M | -$129.7M | -$108.1M | -$96.4M |
| Net income | -$59.6M | -$69.8M | -$123.5M | -$106.5M | -$95.4M |
| Diluted EPS | -$1.01 | -$1.44 | -$2.58 | -$2.74 | — |
| Operating cash flow | -$48.2M | -$71.9M | -$104.0M | -$90.4M | -$62.2M |
| Total assets | $13.8M | $52.4M | $119.7M | $225.7M | $254.4M |
| Total liabilities | $50.0M | $38.2M | $49.0M | $45.4M | $43.6M |
| Stockholders' equity | -$36.2M | $14.3M | $70.7M | $180.3M | $210.8M |
| Cash and investments | $7.1M | $49.0M | $111.5M | $215.5M | $245.0M |
| Total debt | $6.2M | $836,000 | $2.5M | $4.0M | $5.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale
|
Oct 20, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 29, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 28, 2026 | Aug 26, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 16, 2026 | Jul 16, 2026 |
| ARS | Annual report to shareholders | Jun 3, 2026 | Dec 31, 2025 |
All 509 Bioatla, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.